Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
March 22, 2024 07:00 ET
|
Pharmazz, Inc.
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin®) as a resuscitative agent
A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 clinical trial of Sovateltide for the treatment of acute cerebral ischemic stroke patients
October 02, 2023 07:25 ET
|
Pharmazz, Inc.
Special Protocol Assessment Agreement Reached Between Pharmazz, Inc. and the U.S. Food and Drug Administration for Phase 3 Clinical Trial of Sovateltide
Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India
September 14, 2023 00:30 ET
|
Pharmazz, Inc.
Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptomsIndia is the first global territory where Tyvalzi™...
Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients
May 31, 2023 09:19 ET
|
Pharmazz, Inc.
The proportion of acute cerebral ischemic stroke patients with the mRS of 0-2 on day 90 post-randomization was statistically significant (p=0.002) Sovateltide is a first-in-class drug that...
Pharmazz Inc. Announces Key Publications Regarding the Role of Adrenergic Receptors in Venous Blood Return to Treat Shock
March 20, 2023 07:30 ET
|
Pharmazz, Inc.
Centhaquine (Lyfaquin®) is an adrenergic agent that increases cardiac preload by activating alpha2B adrenergic receptors to increase venous blood return to the heart and decreases cardiac afterload by...
Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke
October 31, 2022 08:00 ET
|
Pharmazz, Inc.
Sovateltide produced statistically significant and clinically meaningful improvements in neurological outcomes in acute cerebral ischemic stroke patients and was well tolerated Clinical trial results...
Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress
October 26, 2022 08:00 ET
|
Pharmazz, Inc.
WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...
Pharmazz Inc. Presents Data From its Positive Phase III Study of Centhaquine (PMZ-2010) as a Resuscitative Agent in Hypovolemic Shock Patients at Upcoming Military Health System Research Symposium
September 13, 2022 07:00 ET
|
Pharmazz, Inc.
WILLOWBROOK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...
Pharmazz Inc. announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to conduct a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates
August 29, 2022 08:00 ET
|
Pharmazz, Inc.
Sovateltide is an endothelin-B receptor agonist that is neuroprotective, neurorestorative, and produces neurovascular remodeling Sovateltide marketing authorization for the treatment of acute...
Pharmazz Inc. Announces Positive Results of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke
May 25, 2022 08:00 ET
|
Pharmazz, Inc.
Sovateltide produced a statistically significant and clinically meaningful improvement in neurological outcomes in acute cerebral ischemic stroke patients 90 days post-treatment Sovateltide...